Please ensure Javascript is enabled for purposes of website accessibility

With the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?

By Kody Kester - Jul 17, 2021 at 6:48AM

Key Points

  • The United Kingdom's CMA clearance marked the final step in the company's quest to shore up its orphan drug market presence.
  • The combined company will be bolstered by an impressive orphan drug portfolio that includes Tagrisso, Imfinzi, Lynparza, Soliris, Ultomiris, and Strensiq.
  • Expanded market share is likely to drive solid revenue and earnings growth for AstraZeneca over the next decade.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.

This week, pharma and biotech giant AstraZeneca (AZN 3.08%) cleared its final hurdle in the proposed acquisition of orphan drug pharma company Alexion Pharmaceuticals (ALXN) when it announced that the deal had received clearance from the United Kingdom's Competition and Markets Authority (CMA) on July 14.

The $39 billion acquisition, which was announced last December and unanimously approved by boards of directors at both AstraZeneca and Alexion Pharmaceuticals -- as well as overwhelmingly supported by shareholders of both companies -- will "create a leader in immunology and precision medicines," as AstraZeneca CFO Marc Dunoyer put it in May.

A medical provider examines the heart of a pediatrics patient.

Image Source: Getty Images.

As a result of preceding approvals from regulatory bodies (i.e., the European Commission's clearance earlier this month and clearance from the U.S. Federal Trade Commission in April), AstraZeneca expects its acquisition of Alexion Pharmaceuticals to close on July 21.

AstraZeneca is on the verge of dominating the market for rare disorders

AstraZeneca's decision to acquire Alexion Pharmaceuticals looks promising. Dunoyer lauded Alexion Pharmaceuticals as "a pioneer in the discovery and development of medicines for rare diseases," and it's safe to assume that AstraZeneca's move was prompted by market research such as that produced by firm Insight Slice, which is forecasting a 10% compound annual growth rate in the global orphan drug market from an estimated $148 billion in 2019 to $413 billion by 2030.

AstraZeneca's notable orphan drug blockbusters (including non-small cell lung cancer drugs Tagrisso and Imfinzi and pancreatic cancer drug Lynparza) brought in more than $8 billion in combined 2020 sales, making up about 5% of the estimated $163 billion in 2020 global orphan drug revenue. Once the deal to acquire Alexion Pharmaceuticals closes, the company's orphan drug portfolio will be boosted by the additions of key drugs including Soliris, Ultomiris, and Strensiq, which combined generated about $6 billion in revenue for Alexion Pharmaceuticals in 2020.

When the deal closes, the combined company's 2020 orphan drug market share would be boosted from 5% to 9% -- and that's not even considering Alexion Pharmaceuticals' robust orphan drug pipeline. If we factor in even a very slight increase in AstraZeneca's orphan drug market share -- say, from 9% in 2020 to 10% in 2030 -- the massive growth of the market that is expected to occur over that time brings us astounding results: AstraZeneca's orphan drug revenue would triple from $14 billion in 2020 to $41 billion by 2030.

An exciting opportunity now

Given that AstraZeneca's total 2020 revenue, independent of Alexion Pharmaceuticals, was $27 billion, the orphan drug market alone will likely be enough to meaningfully contribute to the company's top and bottom-line growth over the next decade.

Using this rationale, I believe that AstraZeneca is a good buy under $60 for investors who are seeking the potential for significant capital appreciation by 2030 -- and the market-beating 2.4% dividend yield is a nice bonus in the meantime. 

Kody Kester has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.64 (3.08%) $1.99
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.